JP2016518440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518440A5 JP2016518440A5 JP2016513452A JP2016513452A JP2016518440A5 JP 2016518440 A5 JP2016518440 A5 JP 2016518440A5 JP 2016513452 A JP2016513452 A JP 2016513452A JP 2016513452 A JP2016513452 A JP 2016513452A JP 2016518440 A5 JP2016518440 A5 JP 2016518440A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- dose pharmaceutical
- low dose
- azulene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- NFGVHWUWINDVLR-UHFFFAOYSA-N 2-[(5-hydroxy-3-oxo-8-thia-2,6-diazatricyclo[7.5.0.02,7]tetradeca-1(9),4,6-triene-4-carbonyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)c1c(O)nc2sc3CCCCCc3n2c1=O NFGVHWUWINDVLR-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- -1 azulene-3-carbonyl Chemical group 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 description 15
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 15
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000004953 colonic tissue Anatomy 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1718MU2013 | 2013-05-14 | ||
| IN1718/MUM/2013 | 2013-05-14 | ||
| IN2309MU2013 | 2013-07-09 | ||
| IN2309/MUM/2013 | 2013-07-09 | ||
| PCT/IB2014/000707 WO2014184631A1 (en) | 2013-05-14 | 2014-05-12 | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518440A JP2016518440A (ja) | 2016-06-23 |
| JP2016518440A5 true JP2016518440A5 (https=) | 2017-06-15 |
| JP6407974B2 JP6407974B2 (ja) | 2018-10-17 |
Family
ID=50896342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513452A Expired - Fee Related JP6407974B2 (ja) | 2013-05-14 | 2014-05-12 | 炎症性腸疾患の処置のためのチアゾロピリミジノンの使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9610247B2 (https=) |
| EP (1) | EP2996693B1 (https=) |
| JP (1) | JP6407974B2 (https=) |
| KR (1) | KR102239649B1 (https=) |
| CN (1) | CN105209043B (https=) |
| AU (1) | AU2014266968B2 (https=) |
| BR (1) | BR112015028581B1 (https=) |
| CA (1) | CA2912011C (https=) |
| CY (1) | CY1121280T1 (https=) |
| DK (1) | DK2996693T3 (https=) |
| EA (1) | EA030590B1 (https=) |
| ES (1) | ES2712705T3 (https=) |
| HR (1) | HRP20190315T1 (https=) |
| HU (1) | HUE042691T2 (https=) |
| IL (1) | IL242490B (https=) |
| LT (1) | LT2996693T (https=) |
| MX (1) | MX358198B (https=) |
| MY (1) | MY179215A (https=) |
| PH (1) | PH12015502560B1 (https=) |
| PL (1) | PL2996693T3 (https=) |
| PT (1) | PT2996693T (https=) |
| RS (1) | RS58423B1 (https=) |
| SG (1) | SG11201509275PA (https=) |
| SI (1) | SI2996693T1 (https=) |
| SM (1) | SMT201900111T1 (https=) |
| TW (1) | TWI661828B (https=) |
| UA (1) | UA117244C2 (https=) |
| WO (1) | WO2014184631A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11324829B2 (en) * | 2016-03-14 | 2022-05-10 | Santen Pharmaceutical Co., Ltd. | Antiseptic agent comprising meglumine or salt thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962530B2 (en) * | 2007-06-27 | 2015-02-24 | Regents Of The University Of Colorado | Inflammatory bowel disease therapies |
| TWI500623B (zh) * | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| US8541430B2 (en) * | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
-
2014
- 2014-05-09 TW TW103116529A patent/TWI661828B/zh not_active IP Right Cessation
- 2014-05-12 SM SM20190111T patent/SMT201900111T1/it unknown
- 2014-05-12 HR HRP20190315TT patent/HRP20190315T1/hr unknown
- 2014-05-12 CN CN201480028313.6A patent/CN105209043B/zh not_active Expired - Fee Related
- 2014-05-12 DK DK14728622.3T patent/DK2996693T3/en active
- 2014-05-12 AU AU2014266968A patent/AU2014266968B2/en not_active Ceased
- 2014-05-12 RS RS20190216A patent/RS58423B1/sr unknown
- 2014-05-12 ES ES14728622T patent/ES2712705T3/es active Active
- 2014-05-12 UA UAA201512299A patent/UA117244C2/uk unknown
- 2014-05-12 LT LTEP14728622.3T patent/LT2996693T/lt unknown
- 2014-05-12 US US14/890,131 patent/US9610247B2/en not_active Expired - Fee Related
- 2014-05-12 CA CA2912011A patent/CA2912011C/en active Active
- 2014-05-12 EA EA201592159A patent/EA030590B1/ru not_active IP Right Cessation
- 2014-05-12 JP JP2016513452A patent/JP6407974B2/ja not_active Expired - Fee Related
- 2014-05-12 PL PL14728622T patent/PL2996693T3/pl unknown
- 2014-05-12 MX MX2015015682A patent/MX358198B/es active IP Right Grant
- 2014-05-12 SI SI201431085T patent/SI2996693T1/sl unknown
- 2014-05-12 SG SG11201509275PA patent/SG11201509275PA/en unknown
- 2014-05-12 WO PCT/IB2014/000707 patent/WO2014184631A1/en not_active Ceased
- 2014-05-12 KR KR1020157033744A patent/KR102239649B1/ko not_active Expired - Fee Related
- 2014-05-12 HU HUE14728622A patent/HUE042691T2/hu unknown
- 2014-05-12 EP EP14728622.3A patent/EP2996693B1/en active Active
- 2014-05-12 MY MYPI2015704098A patent/MY179215A/en unknown
- 2014-05-12 BR BR112015028581-3A patent/BR112015028581B1/pt not_active IP Right Cessation
- 2014-05-12 PT PT14728622T patent/PT2996693T/pt unknown
-
2015
- 2015-11-08 IL IL242490A patent/IL242490B/en active IP Right Grant
- 2015-11-10 PH PH12015502560A patent/PH12015502560B1/en unknown
-
2017
- 2017-02-22 US US15/439,733 patent/US10471005B2/en not_active Expired - Fee Related
-
2019
- 2019-02-21 CY CY20191100221T patent/CY1121280T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11298403B2 (en) | Therapeutic agent for inflammatory bowel disease | |
| JP6931004B2 (ja) | ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法 | |
| JP2020510016A5 (https=) | ||
| BRPI0608152A2 (pt) | formulações para tratamento ocular | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2002522485A5 (https=) | ||
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| ES2664951T5 (es) | Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica | |
| JP2015535247A5 (https=) | ||
| JP2020500864A5 (https=) | ||
| DK2656850T3 (en) | Oligonucleotides for the treatment or alleviation of EDEMA | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2017534652A5 (https=) | ||
| JP2008534503A5 (https=) | ||
| US7989479B2 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
| JP6655625B2 (ja) | ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用 | |
| JP2016518440A5 (https=) | ||
| WO2022253034A1 (zh) | 吡咯并嘧啶类化合物的用途 | |
| KR101901001B1 (ko) | PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물 | |
| RU2014126070A (ru) | Способы лечения и предотвращения глазных заболеваний | |
| Sánchez-Ortega et al. | Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease | |
| CN110051848A (zh) | 药物组合、应用以及抗肿瘤的药物 | |
| JP2023541214A (ja) | オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物 | |
| CN105541838B (zh) | 一种治疗肾结石的药物组合物 | |
| RU2724341C1 (ru) | Комбинированная композиция для предупреждения или лечения рака, содержащая производные бензофенонтиазола в качестве vda и ингибитор топоизомеразы |